EGFR and adenocarcinoma: To date, no standard therapeutic regimen for LMC has been established and treatment outcomes have not been evaluated in patients with lung cancer because of its rarity and heterogeneity.9 In particular, in cases of adenocarcinoma there are limited data on the effectiveness of EGFR‐TKI and other chemotherapeutic agents.